Burt Adelman, M.D., is a thought leader and expert in drug development with 32 years of experience in the biotechnology industry. Dr. Adelman was Chairman of the Board and co-founder of Verve Therapeutics, a clinical stage public biotechnology company using base editing drug candidates to prevent atherosclerosis, recently acquired by Eli Lilly. He served as Executive Vice President and Chief Medical Officer at Dyax Corp, where he led development of lanadelumab (Takhzyro). Prior to Dyax, Dr. Adelman held multiple leadership roles at Sesen Bio (formerly Eleven Biotherapeutics), most recently as Interim President of Research and Development. Dr. Adelman began his career at Biogen, where he held roles of increasing responsibility during a 16-year tenure, including Vice President of Regulatory Affairs, Executive Vice President of Research and Development, and Executive Vice President of Portfolio Strategy. He is Co-founder and Chairman of Clear Creek Bio and a former member of the boards of directors of Sirona Medical Technologies and Catabasis Bio. He was Special Advisor to Novo Ventures (US) Inc. and the Novo Broad Greenhouse and is a past member of the Investment Committee of Partners (Mass General and Brigham and Women’s Hospital) Investment Fund. Dr. Adelman holds a B.S. in Biology from Trinity College and an M.D. from Cornell Medical College. He completed residency training and a hematology fellowship at the Peter Bent Brigham Hospital.